Kyowa Kirin Co., Ltd. · TSE:4151
Kyowa Kirin — Technical Presentation (September 2026)
16 slides from Kyowa Kirin's technical presentation, Sep 9, 2026
Slide 1: Topline Results of the KHK4951 Phase 2 study in nAMD patients
Topline Results of the KHK4951 Phase 2 study in nAMD patients September 9th, 2026 Chief Medical Officer (CMO) Yoshifumi Torii Kyowa Kirin Co., Ltd. NCT06116890
Slide 2: Forward-looking statements disclaimer
This document contains forward-looking statements regarding the outlook, targets, plans, and other future-related matters of the Company (including its consolidated subsidiaries in Japan and overseas). These statements are based on our reasonable judgments using current information and forecasts but
Slide 3: Vision 2030
Vision 2030 Provide pharmaceuticals for unmet medical needs Kyowa Kirin will realize the successful creation and delivery of life-changing We are focused on developing medicines value* that ultimately makes people for diseases where there is a clear smile, as a Japan-based Global patient need for ne
Slide 4: KHK4951 assets in focus disease areas
Creating Innovative Assets in focus disease areas Strategic Partnering Assets Life-changing value KHK4951 In development for neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) Pursuing the potential to deliver the first anti-VEGF eye drop treatment for diseases wher
Slide 5: KHK4951 Phase 2 Summary of Test Results
KHK4951 Phase 2 Summary of Test Results Achieved the company's pre-defined product profile targets Results suggest the potential of an eye drop-centered maintenance treatment strategy Effectiveness Primary Safety and Secondary Evaluation Items Tolerability Evaluation Items In all treatment groups, T
Slide 6: Clinical Needs for Eye Drop Maintenance Therapy in nAMD
Clinical Needs for Eye Drop Maintenance Therapy in nAMD Diseases requiring ongoing treatment 01 nAMD requires ongoing intravitreal injection therapy with anti-VEGF agents and follow-up to maintain long- term vision Burden of current treatment 02 Treatment with intravitreal injections places a signif
Slide 7: The Concept of KHK4951 as Eye Drop Maintenance Therapy
The Concept of KHK4951 as Eye Drop Maintenance Therapy Current Maintenance Therapy by Intravitreal Maintenance Therapy Models Examined in Injection KHK4951 • Focusing on extending the • Maintenance therapy mainly interval between intravitreal involves daily eye drops injections • Daily self-manageme
Slide 8: KHK4951 Design of Phase 2 Trials
KHK4951 Design of Phase 2 Trials Three groups were set up according to the dosage 1. Twice daily; 2. Once-daily administration Follow-up after Screening Treatment (52W) treatment (4W) 1 KHK4951 2 w/v%、BID1 EoT/ET IVT EoS Screening 2 KHK4951 2 w/v%、QD2 3 KHK4951 0.5 w/v%、QD D-30 D1 W8 W52 W56 Overvie
Slide 9: Approximately 65–69% maintained vision within 15 letters
Approximately 65–69% of cases in all treatment groups maintained their vision within 15 letters decrease in BCVA without any rescue IVT injection ■15 or more letters decrease in BCVA: 31.1% (2.0% BID), 34.9% (2.0% QD), 31.8% (0.5% QD) ■No significant differences were observed among dose groups, and
Slide 10: Mean change in BCVA during the KHK4951 dosing period
Mean change in BCVA during the KHK4951 dosing period In all groups, the mean BCVA remained stable from the KHK4951 administration. No clear differences were observed in the mean BCVA change among dose groups. 10 © Kyowa Kirin Co., Ltd.
Slide 11: Mean change in CST during the KHK4951 dosing period
Mean change in CST during the KHK4951 dosing period In all groups, the mean CST remained stable from the KHK4951 administration. Meanwhile, no clear differences were observed in the mean CST change among dose groups. ILM: Internal Limiting Membrane RPE: Retinal pigment epithelium 11 © Kyowa Kirin Co
Slide 12: Safety and Tolerability
Safety and Tolerability No new safety signals were observed in this study Parameter Main findings A small number of dry eyes and punctate keratitis were mainly observed in the 2.0% Ocular site BID cohort No significant new safety signals observed during KHK4951 treatment (e.g., increase Systemic in
Slide 13: Clinical Perspectives on Eye-Drop Maintenance Therapy — KOL Comments
Clinical Perspectives on Eye-Drop Maintenance Therapy — KOL Comments KOLs Feedbacks Dr. Pieramici ⚫ Although the absence of a true control group is the study’s primary limitation, making it difficult to attribute the observed outcomes directly to the drug, Dr. Pieramici noted that approximately 70%
Slide 14: Summary and Conclusion
Summary and Conclusion Achieved the company's pre-defined product profile targets Results suggest the potential of an eye drop-centered maintenance treatment strategy Secondary Endpoints In all groups, BCVA and CST remained stable throughout Efficacy Evaluation the treatment period. Approximately 65
Slide 15: Creating Life-changing value
Kyowa Kirin continuously creates Life-changing value by leveraging disease science and drug discovery technology From Story for Vision 2030 Disease Science Deeply Exploring Unmet Medical Needs (UMN) of Diseases, Their Causes, and Mechanisms ・Exploring treatment possibilities starting from unmet pati
Slide 16: Contact for Inquiries Regarding This Material
～Contact for Inquiries Regarding This Material～ Kyowa Kirin Co., Ltd. Finance Dep., IR Group +81-3-5205-7206 / ir@kyowakirin.com
Kyowa Kirin — Technical Presentation (September 2026) on 6ix